J&J’s Invokana closes on diabetic kidney disease approval

J&J’s Invokana closes on diabetic kidney disease approval

Source: 
Pharmaforum
snippet: 

The US FDA has granted a priority review to Johnson & Johnson’s Invokana in diabetic kidney disease, signposting an end to a 20-year drought on new therapies.